In vivo CRISPR screens identifyMgaas an immunotherapy target in triple-negative breast cancer
Open Access
- 19 September 2024
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (39)
Abstract
Immune evasion is not only critical for tumor initiation and progression, but also determines the efficacy of immunotherapies. Through iterative in vivo CRISPR screens with seven syngeneic tumor models, we identified core and context-dependent immune evasion pathways across cancer types. This valuable high-confidence dataset is available for the further understanding of tumor intrinsic immunomodulators, which may lead to the discovery of effective anticancer therapeutic targets. With a focus on triple-negative breast cancer (TNBC), we found thatMgaknock-out significantly enhances antitumor immunity and inhibits tumor growth. Transcriptomics and single-cell RNA sequencing analyses revealed that Mga influences various immune-related pathways in the tumor microenvironment. Our findings suggest that Mga may play a role in modulating the tumor immune landscape, though the precise mechanisms require further investigation. Interestingly, we observed that low MGA expression in breast cancer patients correlates with a favorable prognosis, particularly in those with active interferon-γ signaling. These observations provide insights into tumor immune escape mechanisms and suggest that further exploration of MGA’s function could potentially lead to effective therapeutic strategies in TNBC.Keywords
Funding Information
- Cancer Prevention and Research Institute of Texas (RP160667 RP180813)
- HHS | NIH | National Cancer Institute (CA193124 CA210929 CA216911 CA216437 CA274234 CA275712)
- HHS | National Institutes of Health (R35GM130119)
This publication has 53 references indexed in Scilit:
- Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1Cell Death & Differentiation, 2023
- Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responsesCancer Cell, 2022
- In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy targetCell, 2021
- Natural Killer Cells Suppress T Cell-Associated Tumor Immune EvasionCell Reports, 2019
- Emerging insights into HAUSP (USP7) in physiology, cancer and other diseasesSignal Transduction and Targeted Therapy, 2018
- In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy targetNature, 2017
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in miceNature Communications, 2017
- ATF7IP-Mediated Stabilization of the Histone Methyltransferase SETDB1 Is Essential for Heterochromatin Formation by the HUSH ComplexCell Reports, 2016
- The ins and outs of MHC class II-mediated antigen processing and presentationNature Reviews Immunology, 2015
- Hallmarks of Cancer: The Next GenerationCell, 2011